In 1991, a small annual meeting named "International Winter Conference on Neurodegeneration (lWCN)" was established; the aim of this meeting is to review the neurodegenerative disorders and to attempt to explore how progress might be made in this field, as the neurodegenerative disorders have been emerging to be one of the major causes of morbidity and mortality in modern societies. The first meeting took place in Seefeld, Austria, in February 1992; the topics for the first IWCN were chosen to provide a broad foundation of clinical science, which included the problem of aging, classification of neurodegenerative disorders and of Alzheimer's dis natural history, pathology, and clinical neurology ease, Parkinson's disease, and amyotrophic lateral sclerosis. The fundamental pathology underlying these neurodegenerative disorders is neuronal cell death. For the understanding of pathophysiol ogy and the development of neuroprotective treatment for these dis orders, elucidation of the mechanism of neuronal cell death at the cellular and molecular level is essential. With this concept in mind, the second IWCN was held in Whistler Village in Canada in January 1993. Funding was generously provided by Schering AG, Berlin, and for the excellent organization we have to thank Ms. Ingeborg Runge.

The 10th International Winter Conference on Neurodegeneration (lWCN) has taken place from February 14-16,2002, at the lovely "SchloB Ziethen", an old prussian manor (in Prussia, 'faute de mieux', called 'SchloB', i. e. cas- tle or residence). This place is 20 km off Tegel Airport, Berlin's main airport, and has been beautifully restored by baroness Edith von Thiingen (nee von BUlow, i. e. of historical Prussian aristocracy); it lends itself rather perfectly for the IWCN type of small interdisciplinary workshops on neurodegenera- tion which combine short lectures with plenty of discussion. In this context, we could quote Alexander von Humboldt's famous opening words for one of the first international scientific meetings held at Berlin, on September 18, 1828: "The main purpose ...does not consist in a mutual reading of manuscripts all to be printed after at least one year in specialised publications, but in the personal communication amongst those who work in similar scientific fields; the oral and thus more stimulating exchange of ideas, might they represent facts, opinions or doubts; the foundation of friendly relations which convey illumination to our sciences, serene grace to our lives and tolerance and mildness to our habits . ..Berlin, Sept. 18, 1828 Alexander von Humboldt To the IWCN aficionado, it may come as a little surprise that this is the pub- lication of the 10th Winter Conference as this might mean that they must have missed number 9.

The 10th International Winter Conference on Neurodegeneration (lWCN) has taken place from February 14-16,2002, at the lovely "SchloB Ziethen," an old prussian manor (in Prussia, 'faute de mieux', called 'SchloB', i. e. cas tle or residence). This place is 20 km off Tegel Airport, Berlin's main airport, and has been beautifully restored by baroness Edith von Thiingen (nee von BUlow, i. e. of historical Prussian aristocracy); it lends itself rather perfectly for the IWCN type of small interdisciplinary workshops on neurodegenera tion which combine short lectures with plenty of discussion. In this context, we could quote Alexander von Humboldt's famous opening words for one of the first international scientific meetings held at Berlin, on September 18, 1828: "The main purpose . . . does not consist in a mutual reading of manuscripts all to be printed after at least one year in specialised publications, but in the personal communication amongst those who work in similar scientific fields; the oral and thus more stimulating exchange of ideas, might they represent facts, opinions or doubts; the foundation of friendly relations which convey illumination to our sciences, serene grace to our lives and tolerance and mildness to our habits . . . Berlin, Sept. 18, 1828 Alexander von Humboldt To the IWCN aficionado, it may come as a little surprise that this is the pub lication of the 10th Winter Conference as this might mean that they must have missed number 9."

The 8th International Winter Conference on Neurodegeneration from Febru- ary 9 to 13, 2000 took place in Tegernsee, Bavaria, Germany. The interest shown in this symposium, which was carried by invited speakers only, was striking. 28 lectures in 5 sessions dealt with themes on basic science and therapy strategies for neurodegenerative illness. This time especially basic mechanism of cell death and resulting causal treatment possibilities were centre themes of the lectures and lively discussions. In accordance with tradi- tion 5 lectures on Multiple Sclerosis finished the convention. 60 scientists from 13 countries discussed current questions to these themes. The Symposium started with a lecture on the history of the develop- ment of modern-L-DOPA-therapy. Lectures on cell death of dopaminergic nerve cells, new valuation regarding assembly, built up and function of neuromelanin of Substantia nigra and with this, the question of the physio- logic and pathobiochemical role of dopamine and neuromelanin built the first block of themes which consequently extended to molecular and genetic aspects of cell death. Highlights of the symposium were neuroprotective and neuroregenerative future therapy strategies together with discussions on the difficulties of clinical neuroprotection. Developmental biological aspects on nerve cells, reorganisation and neurodegeneration showed a stimulating point of view of momentary and future development possibilities of new and more causal forms of therapy of neurodegenerative illness.

Neurodegeneration is one of the most important subjects of the investigation now and in the coming 21st century. Alzheimer's disease is the leading cause of dementia in the elderly people and Parkinson's disease is one of the major neurologic disorders with the prevalence between 1 and 2/1 000 population in advanced countries. Many others are suffering from intractable neurodegener ative disorders such as amyotrophic lateral sclerosis, Huntington's disease, or spinocerebellar degeneration. No truly effective treatment is available for any of these neurodegenerative disorders except for Parkinson's disease; even in Parkinson's disease, still it is impossible to slow down the disease process with the currently available treatment. It is urgently needed to develop new effective technique to halt or slow down the disease process in each of those disorders. Recent advance in the molecular biological and molecular genetic technique has brought us great progress in the understanding of etiology and pathogenesis of these disorders, but still it is not known how neurons are going to die in these disorders. To explore the question, mutual cooperation and exchange of ideas between basic scientists and clinical peoples are of utmost importance."

Volume 5 of the series "Advances in Research on Neurodegeneration" is concerned with themes which are currently the focus of intensive research, and in which advances in our understanding of the pathological mechanisms un derlying neurodegenerative diseases are expected in the near future. The first section contains five reviews devoted to the various neuroimaging technolo gies. The discussion is concerned with the question of whether neuroimaging techniques make it possible to follow the process of degeneration as it occurs, and which methods offer the required sensitivity and quantifiability for this purpose. However, the question needs to be examined of whether, given the physical and chemical limitations of these techniques, even under optimal conditions, anatomical resolution can be improved to the extent that neuro degenerative diseases can be diagnosed earlier than currently possible and a confident diagnosis made. The possibilities of using neuroimaging techniques to provide information regarding the effects of neuroprotective or neuroregen erative therapeutic strategies, and for correlating the results of neuropsycho logical research with imaging data are also discussed. The second section is concerned with the significance of endogenous or exogenous neurotoxins as triggers for neurodegenerative processes that may lead to Parkinsonism. Vulnerability factors, which include such factors as nerve ending sensitivity, the synergistic effects of drugs and the various mechanisms underlying different toxins are discussed."

Jetzt vollstandig uberarbeitet und in allen Teilen aktualisiert: Auch die 3. Auflage dieses bewahrten Lehrbuchs bietet wieder alles, was man uber die Pharmakologie und Toxikologie wissen muss. Umfassend und zugleich kompakt bietet es einen hervorragenden UEberblick uber die Wirkungen der wichtigsten Arzneistoffe und -stoffklassen.

Wir sehen in der Natur nicht Worter, sondern immer nur Anfangsbuchstaben von Wortern, und wenn wir alsdann lesen wollen, so finden wir, daft die neuen sogenannten Worter wiederum bloft Allfangsbuchstaben von andren sind. (Georg Christoph Lichtenberg. 1742-1799) Sudelbuch II Der zweite und letzte Teil des Taschenbuches "Pharmakologie und Toxiko logie" umfaJ3t die Kapitel: - Pharmaka mit Wirkung auf das Nervensystem, - Pharmaka mit Wirkung auf Herz, Kreislauf und Blut, - Pharmaka mit Wirkung auf Niere, Saure-Basenhaushalt und Elektrolyte, - Pharmaka mit Wirkung auf den Respirationstrakt und - Pharmaka mit Wirkung auf den Verdauungstrakt. Die Leitsatze, die mich beim Schreiben des ersten Teils bewegten, gelten natiirlich auch fUr den zweiten Teil. Mein Ziel war und ist es, eine EinfUh rung in die Pharmakologie und Toxikologie zu schreiben, die den Ausbil dungs stand der Studierenden der Pharmazie in den medizinischen Grund lagenfachern berucksichtigt und in kurzer und iibersichtlicher Form Pharmakodynamik, Pharmakokinetik und Anwendung einzelner Wirkstof fe oder Wirkstoffgruppen nach ihrer Bedeutung in der klinischen Anwen dung vorzustellen. Wieder habe ich versucht, einer klaren und verstandli chen, manchmal auch bewuJ3t vereinfachenden, Darstellung wichtiger Arzneimittel den Vorzug vor einer liickenlosen Wiedergabe zu geben. Aus Platzgriinden und urn den Charakter eines Taschenbuches zu wah ren, habe ich darauf verzichtet, aIle Handelspraparate eines Pharmakons in die entsprechenden Tabellen aufzunehmen. Die Beispiele stellen natiirlich keine Wertung dar."